Disease Information

General Information of the Disease (ID: DIS00380)

• Name: Mature T-cell and Nk-cell lymphoma
• ICD: ICD-11: 2B0Y

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Tofacitinib

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Tyrosine-protein kinase JAK3 (JAK3) [1]

• Sensitive Disease: Mature T-cell and Nk-cell lymphoma [ICD-11: 2B0Y.0]
• Molecule Alteration: Missense mutation; p.A572V (c.1715C>T)
• Sensitive Drug: Tofacitinib
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: NK-S1 cells; N.A.; .; N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: MTS assay
• Mechanism Description: The missense mutation p.A572V (c.1715C>T) in gene JAK3 cause the sensitivity of Tofacitinib by aberration of the drug's therapeutic target

References

• Ref 1: Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaCancer Discov. 2012 Jul;2(7):591-7. doi: 10.1158/2159-8290.CD-12-0028. Epub 2012 Jun 15.